Logo

Mirati Signs a Non-Exclusive Clinical Collaboration Agreement with Verastem to Evaluate Adagrasib + VS-6766 for KRASG12C-Mutant NSCLC

Share this

Mirati Signs a Non-Exclusive Clinical Collaboration Agreement with Verastem to Evaluate Adagrasib + VS-6766 for KRASG12C-Mutant NSCLC

Shots:

  • The companies collaborated to evaluate the safety, tolerability, and efficacy of Mirati's adagrasib (KRASG12C inhibitor) + Verastem's VS-6766 (RAF/MEK inhibitor) in the P-I/II trial for KRASG12C-mutant NSCLC. The trial is based on the results from the preclinical studies
  • The primary objective is to determine the maximum tolerated dose and RP2D for the combination of adagrasib and VS-6766
  • Adagrasib is being evaluated in multiple clinical trials in combination with other anti-cancer therapies in patients with advanced solid tumors & showed a response in monothx. therapy for NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors with KRASG12C mutations

Click here to­ read full press release

Ref: Mirati | Image: Mirati


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions